全文获取类型
收费全文 | 15793篇 |
免费 | 1334篇 |
国内免费 | 482篇 |
专业分类
耳鼻咽喉 | 171篇 |
儿科学 | 281篇 |
妇产科学 | 376篇 |
基础医学 | 2082篇 |
口腔科学 | 319篇 |
临床医学 | 1842篇 |
内科学 | 2867篇 |
皮肤病学 | 308篇 |
神经病学 | 1076篇 |
特种医学 | 641篇 |
外国民族医学 | 3篇 |
外科学 | 1930篇 |
综合类 | 1146篇 |
一般理论 | 2篇 |
预防医学 | 1014篇 |
眼科学 | 442篇 |
药学 | 1393篇 |
4篇 | |
中国医学 | 335篇 |
肿瘤学 | 1377篇 |
出版年
2024年 | 26篇 |
2023年 | 156篇 |
2022年 | 401篇 |
2021年 | 593篇 |
2020年 | 318篇 |
2019年 | 428篇 |
2018年 | 423篇 |
2017年 | 375篇 |
2016年 | 386篇 |
2015年 | 538篇 |
2014年 | 628篇 |
2013年 | 690篇 |
2012年 | 1129篇 |
2011年 | 1197篇 |
2010年 | 711篇 |
2009年 | 596篇 |
2008年 | 870篇 |
2007年 | 847篇 |
2006年 | 817篇 |
2005年 | 767篇 |
2004年 | 693篇 |
2003年 | 595篇 |
2002年 | 519篇 |
2001年 | 463篇 |
2000年 | 400篇 |
1999年 | 395篇 |
1998年 | 149篇 |
1997年 | 151篇 |
1996年 | 176篇 |
1995年 | 146篇 |
1994年 | 107篇 |
1993年 | 85篇 |
1992年 | 195篇 |
1991年 | 182篇 |
1990年 | 156篇 |
1989年 | 134篇 |
1988年 | 128篇 |
1987年 | 106篇 |
1986年 | 105篇 |
1985年 | 103篇 |
1984年 | 77篇 |
1983年 | 70篇 |
1982年 | 56篇 |
1981年 | 55篇 |
1980年 | 47篇 |
1979年 | 60篇 |
1978年 | 50篇 |
1977年 | 33篇 |
1975年 | 27篇 |
1974年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
993.
994.
This study was performed to develop a new nonparametric approach for the estimation of robust tissue-to-plasma ratio from extremely sparsely sampled paired data (ie, one sample each from plasma and tissue per subject). Tissue-to-plasma ratio was estimated from paired/unpaired experimental data using independent time points approach, area under the curve (AUC) values calculated with the naive data averaging approach, and AUC values calculated using sampling based approaches (eg, the pseudoprofile-based bootstrap [PpbB] approach and the random sampling approach [our proposed approach]). The random sampling approach involves the use of a 2-phase algorithm. The convergence of the sampling/resampling approaches was investigated, as well as the robustness of the estimates produced by different approaches. To evaluate the latter, new data sets were generated by introducing outlier(s) into the real data set. One to 2 concentration values were inflated by 10% to 40% from their original values to produce the outliers. Tissue-to-plasma ratios computed using the independent time points approach varied between 0 and 50 across time points. The ratio obtained from AUC values acquired using the naive data averaging approach was not associated with any measure of uncertainty or variability. Calculating the ratio without regard to pairing yielded poorer estimates. The random sampling and pseudoprofile-based bootstrap approaches yielded tissue-to-plasma ratios with uncertainty and variability. However, the random sampling approach, because of the 2-phase nature of its algorithm, yielded more robust estimates and required fewer replications. Therefore, a 2-phase random sampling approach is proposed for the robust estimation of tissue-to-plasma ratio from extremely sparsely sampled data. 相似文献
995.
996.
The role of Rho kinase activation in the regulation of cardiac contractility and Ca2+ signaling remains unclear, whereas its role in smooth muscle regulation has been well documented. To study the potential role of Rho kinase in the regulation of cardiac contractility and Ca2+ transients induced by endothelin-1 (ET-1) and isoproterenol, we used the Rho kinase inhibitor Y-27632 in rabbit ventricular myocardium and myocytes loaded with indo-1/AM. Y-27632 (3–30 M) inhibited significantly the baseline contractility and Ca2+ transients. Furthermore, Y-27632 suppressed the increase in contractility and Ca2+ transients induced by ET-1 in a concentration-dependent manner, when it was used in a concentration at which it did not affect the effects of isoproterenol via -adrenoceptors. In the presence of Y-27632, ET-1 increased cell shortening in the absence of an increase in Ca2+ transients. This is an indication that the increase in myofilament Ca2+ sensitivity induced by ET-1 is less susceptible to the inhibitory action of Y-27632. These findings imply that the Rho kinase activation may partially contribute to the ET-1-induced regulation of contractility, primarily due to an ET-1-induced increase in Ca2+ transients in rabbit ventricular myocardium. 相似文献
997.
Murren J Modiano M Kummar S Clairmont C Egorin M Chu E Sznol M 《Investigational new drugs》2005,23(2):123-135
Summary Purpose: VNP40101M is a new alkylating agent that demonstrated broad anti-tumor activity in murine tumor models. A phase I trial was initiated to determine the toxicities, maximum tolerated dose, and pharmacokinetics of VNP40101M by short IV infusion. Study design: The starting dose was 3 mg/m2 every four weeks, and was escalated in successive cohorts as follows: 6, 12, 24, 40, 60, 80, and 100 mg/m2. Beyond 100 mg/m2, dose increments were 25%. Initially, 1–2 patients were assigned to a dose level. Intra-patient dose escalation was permitted. With the first instance of a drug-related grade 2 adverse event, all dose levels required assessment of 3–6 patients. Pharmacokinetic parameters were assessed in the first cycle and any cycle with a change in dose. Results: Twenty-six patients in 13 dose levels ranging from 3–305 mg/m2 were evaluated. Dose-related thrombocytopenia was the major toxicity, with the nadir occurring at a median of day 27. At 305 mg/m2, six of eight patients developed grade 3 thrombocytopenia, including one event that met the definition for DLT. Other dose-related toxicities included moderate granulocytopenia, anemia, and a mild infusion-related syndrome consisting of acute headache and facial flushing. The granulocyte nadir occurred at a median of day 34, and recovery of both thrombocytopenia and neutropenia to < grade 2 occurred at a median of day 43. VNP40101M peak plasma concentrations and AUC were linear with dose. The elimination half-life was short and estimated to be approximately 15 minutes. Conclusions: The MTD and recommended dose for phase II trials is 305 mg/m2 every six weeks. Phase II trials in less heavily pre-treated patient populations are warranted.Supported by Vion Pharmaceuticals, Inc. 相似文献
998.
Cyanidin 3-glucoside and peonidin 3-glucoside inhibit tumor cell growth and induce apoptosis in vitro and suppress tumor growth in vivo 总被引:3,自引:0,他引:3
Dietary polyphenols, including anthocyanins, are suggested to be involved in the protective effects of fruits and vegetables against cancer. However, anticancer effects of peonidin 3-glucoside have not been clearly demonstrated, with only limited studies being available concerning the inhibitory effect of cyanidin 3-glucoside for tumor cell growth. Therefore, in this study, we have isolated and identified the two bioactive compounds, peonidin 3-glucoside and cyanidin 3-glucoside, from Oryza sativa L. indica, to treat various cancer cells. The results showed that, among analyzed cell lines, HS578T was the most sensitive to peonidin 3-glucoside and cyanidin 3-glucoside. Treatment with peonidin 3-glucoside or cyanidin 3-glucoside resulted in a strong inhibitory effect on cell growth via G2/M arrest. Regarding cell cyclerelated proteins, peonidin 3-glucoside treatment resulted in down-regulation of protein levels of cyclin-dependent kinase (CDK)-1, CDK-2, cyclin B1, and cyclin E, whereas cyanidin 3-glucoside could decrease the protein levels of CDK-1, CDK-2, cyclin B1, and cyclin D1. In addition, cyanidin 3-glucoside or peonidin 3-glucoside also induced caspase-3 activation, chromatin condensation, and cell death. Furthermore, anthocyanins from O. sativa L. indica were evidenced by their inhibition on the growth of Lewis lung carcinoma cells in vivo. 相似文献
999.
Many quantitative assay measurements of metabolites of environmental toxicants in clinical investigations are subject to left censoring due to values falling below assay detection limits. Moreover, when observations occur in both unexposed individuals and exposed individuals who reflect a mixture of two distributions due to differences in exposure, metabolism, response to intervention and other factors, the measurements of these biomarkers can be bimodally distributed with an extra spike below the limit of detection. Therefore, estimating the effect of interventions on these biomarkers becomes an important and challenging problem. In this article, we present maximum likelihood methods to estimate the effect of intervention in the context of mixture distributions when a large proportion of observations are below the limit of detection. The selection of the number of components of mixture distributions was carried out using both bootstrap-based and cross-validation-based information criterion. We illustrate our methods using data from a randomized clinical trial conducted in Qidong, People's Republic of China. 相似文献
1000.
Kobashigawa J David K Morris J Chu AH Steffen BJ Gotz VP Gordon RD 《Transplantation proceedings》2005,37(2):1333-1339
BACKGROUND: Sparse published data exist on outcomes in daclizumab-treated cardiac transplant patients. One trial observed an increased mortality risk 6 and 12 months posttransplant in patients receiving daclizumab plus mycophenolate mofetil (MMF), cyclosporine, and steroids. This study further investigates the safety profile of daclizumab with this same immunosuppressive regimen from a large registry. METHODS: Data obtained at hospital discharge on all adult cardiac transplants performed in the USA between January 1998 and October 2003 for patients receiving MMF plus cyclosporine and steroids were accessed from the Scientific Registry of Transplant Recipients. Patients were selected based on induction treatment: daclizumab (n = 684) or no induction (n = 2525). Outcomes were evaluated at 6 months, 12 months, and 3 years posttransplant. Univariate Kaplan-Meier and multivariate Cox models were used to evaluate the effect of treatment on outcomes. Patient survival and infectious death were the primary endpoints. Secondary endpoints included rejection within the first year posttransplant (acute rejection; AR) and total rejection episodes over time. The two treatment groups shared similar demographics and transplant procedure details. RESULTS: Daclizumab (vs no induction) patients had no increased risk of patient death nor infectious death. Daclizumab patients had a lower incidence of AR at 6 months (P = .005) and 12 months (P < .001); the adjusted risk for AR at 12 months (hazards ratio [HR] = 0.77; P = .89) and over 3 years (HR 0.83, P = .006) was also lower in daclizumab-treated patients. CONCLUSIONS: In cardiac transplant patients, daclizumab (vs no induction) does not result in increased mortality or infectious death, and is associated with a lower incidence of AR. 相似文献